Gossamer Bio Inc (GOSS) Stock Price, Quote & News

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercia...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 684 1300

Website: www.gossamerbio.com

Address:

3115 Merryfield Row, Suite 120, San Diego, United States

King_of_Bio Mar. 6 at 9:42 PM

$GOSS Still here...and still bullish.

0 · Reply

Invest2live Mar. 6 at 8:28 PM

$TNYA 50% already; congrats 🌿😊🌿 Checkout $GOSS and $ARAY as well as $VERI

1 · Reply

financiallylacking Mar. 6 at 6:47 PM

$GOSS Looks like everyone loaded up. Just waiting for scans or FDA news.

1 · Reply

Finnish_boy Mar. 6 at 12:38 PM

$GOSS

1 · Reply

Almostmadeit Mar. 6 at 10:19 AM

$GOSS https://www.gurufocus.com/news/8682270/oppenheimer-maintains-outperform-rating-lowers-pt-on-gossamer-bio-goss-goss-stock-news

0 · Reply

Finnish_boy Mar. 6 at 9:53 AM

$GOSS I have already my plan in place. I think i will get my losses back✅💪🏼

1 · Reply

f0000 Mar. 6 at 8:09 AM

$GOSS Don’t oversee the signs. Chiesi actively looks for a “PAH / PH-ILD Thought Leader Liaison”. “This newly created position will initially focus on pre-launch preparation in anticipation of FDA approval of our PAH/PH-ILD collaboration asset.” - Mar 4,2026 https://careers.chiesi.com/job/Cary%2C-NC-Thought-Leader-Liaison%2C-PAH-PH-ILD-NC/1329185157/

1 · Reply

StockBoiChris Mar. 6 at 2:32 AM

$GOSS 🤔 ❓

1 · Reply

StockBoiChris Mar. 6 at 2:31 AM

$GOSS 10:1

0 · Reply

Invest_to_grow Mar. 6 at 1:20 AM

$GOSS Simply look at the large scale orders and order distribution flow! Big whales already loaded heavy! Looks like shorts are in trouble here!

0 · Reply

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1

BWAY DH

Mar 1, 2026, 4:07 PM EST - 5 days ago

GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm

Feb 23, 2026, 4:25 PM EST - 11 days ago

Gossamer Bio, Inc. (GOSS) Discusses Topline Results of PROSERA Phase 3 Study in Pulmonary Arterial Hypertension Transcript

Feb 23, 2026, 12:40 PM EST - 11 days ago

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Feb 23, 2026, 11:26 AM EST - 11 days ago

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 23, 2026, 9:57 AM EST - 11 days ago

Gossamer Bio Plans FDA Talks After Narrow Miss In Key Pivotal Study, Stock Sinks

Feb 23, 2026, 8:11 AM EST - 11 days ago

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Feb 23, 2026, 8:00 AM EST - 11 days ago

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Jan 8, 2026, 5:30 PM EST - 2 months ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 24, 2025, 4:01 PM EST - 3 months ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 5, 2025, 4:01 PM EST - 4 months ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Sep 25, 2025, 7:41 AM EDT - 5 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:31 AM EDT - 5 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 22, 2025, 7:31 AM EDT - 5 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 9, 2025, 9:50 AM EDT - 6 months ago

Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout

Aug 29, 2025, 7:31 AM EDT - 6 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 5, 2025, 4:01 PM EDT - 7 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 16, 2025, 7:31 AM EDT - 9 months ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

May 15, 2025, 9:30 PM EDT - 10 months ago

Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:01 PM EDT - 10 months ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 12, 2025, 4:01 PM EDT - 10 months ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 7, 2025, 4:01 PM EDT - 10 months ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 7:42 PM EST - 1 year ago

Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD

Feb 3, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Sep 10, 2024, 1:25 AM EDT - 1 year ago

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 2:39 PM EDT - 1 year ago

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

May 14, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 7, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:46 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

May 6, 2024, 7:30 AM EDT - 1 year ago

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 3, 2024, 8:02 AM EDT - 2 years ago

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Mar 12, 2024, 7:31 AM EDT - 2 years ago

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

Mar 5, 2024, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Dec 13, 2023, 4:01 PM EST - 2 years ago

Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

Dec 5, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

Nov 29, 2023, 7:01 AM EST - 2 years ago

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Nov 9, 2023, 7:31 AM EST - 2 years ago

Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:08 PM EDT - 2 years ago

Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

Sep 7, 2023, 7:44 AM EDT - 2 years ago

Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 24, 2023, 4:16 PM EDT - 2 years ago

Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

King_of_Bio Mar. 6 at 9:42 PM

$GOSS Still here...and still bullish.

0 · Reply

Invest2live Mar. 6 at 8:28 PM

$TNYA 50% already; congrats 🌿😊🌿 Checkout $GOSS and $ARAY as well as $VERI

1 · Reply

financiallylacking Mar. 6 at 6:47 PM

$GOSS Looks like everyone loaded up. Just waiting for scans or FDA news.

1 · Reply

Finnish_boy Mar. 6 at 12:38 PM

$GOSS

1 · Reply

Almostmadeit Mar. 6 at 10:19 AM

$GOSS https://www.gurufocus.com/news/8682270/oppenheimer-maintains-outperform-rating-lowers-pt-on-gossamer-bio-goss-goss-stock-news

0 · Reply

Finnish_boy Mar. 6 at 9:53 AM

$GOSS I have already my plan in place. I think i will get my losses back✅💪🏼

1 · Reply

f0000 Mar. 6 at 8:09 AM

1 · Reply

StockBoiChris Mar. 6 at 2:32 AM

$GOSS 🤔 ❓

1 · Reply

StockBoiChris Mar. 6 at 2:31 AM

$GOSS 10:1

0 · Reply

Invest_to_grow Mar. 6 at 1:20 AM

$GOSS Simply look at the large scale orders and order distribution flow! Big whales already loaded heavy! Looks like shorts are in trouble here!

0 · Reply

Camaro12 Mar. 6 at 12:36 AM

$GOSS just joined with a big position let’s see what happens

0 · Reply

Almostmadeit Mar. 5 at 11:02 PM

$GOSS ok, I could be wrong here. Monday close at $.70. Let’s wait and see!

1 · Reply

Almostmadeit Mar. 5 at 9:51 PM

$GOSS still here, and staying until at least $3. I honestly feel it could go way higher. I couldn’t put much more in, however, I now have another 4500 shares

1 · Reply

Cheaslea76 Mar. 5 at 9:49 PM

$GOSS $1 end of April n I’d and slowly baby

0 · Reply

JackLarson369 Mar. 5 at 9:27 PM

$GOSS Shake out liquidity grab as a bullish hammer formed on an inside day. Another million added on the CMF. Now positive 15.5 million. I couldn't resist myself and bought more at .482. First it'll have to fight 1, then close the gap just above 2. The 3/20 strike date has a lot of 5c that someone is going to fight to make some money back on so I'm expecting a big push very soon. Earnings on 3/11 no doubt going to be an interesting day.

2 · Reply